Long-Term Efficacy and Safety of Pegcetacoplan Over 36 Months
Dr Charles Wykoff presents the latest date from the GAIL extension study evaluating pegcetacoplan for treating geographic atrophy.
Faricimab in the Real World
Dr Arshad Khanani details the key learnings from the real-world evidence generated in the TRUCKEE and TAHOE studies following the FDA approval of faricimab.
Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trials in nAMD
Dr Marco Zarbin presents his talk from the 2023 ASRS annual meeting, where he explores the impact of disease activity criteria on drug durability estimations in clinical trials and includes a comparative analysis across multiple clinical trials in neovascular AMD (age-related macular degeneration).
Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy
In this Rapid Readout, Dr Paul Hahn shares his presentation from the 2023 ASRS annual meeting. This study compares the efficacy of the two FDA-approved treatments for geographic atrophy based on an anchored matching-adjusted indirect comparison of the phase 3 trials.
Individualized Faricimab Dosing up to Every 16 Weeks Maintains Robust Anatomic and Vision Outcomes Through 2 Years in nAMD
Dr Varun Chaudhary shares insights from his presentation at the 2023 ARVO annual meeting, highlighting key findings on personalized treatment interval dosing using faricimab.
Durable Vision Gains and Greater Fluid Control With Extended Faricimab Dosing vs Aflibercept in Patients With DME
In this Rapid Readout, Dr Jennifer Lim shares her presentation from the 2023 ARVO annual meeting, highlighting the visual and anatomic outcomes observed in clinical trials of faricimab when administered according to a personalized treatment algorithm for patients with diabetic macular edema (DME).
The TRUCKEE Study: Real-World Efficacy and Safety of Faricimab in Neovascular AMD
Dr David Almeida shares insights from his presentation at the 14th Annual Congress on Controversies in Ophthalmology (COPHy) in Lisbon, Portugal.
Rapid Readout: Angiopoietin-2 (Ang2) Inhibition in the Treatment of Diabetic Macular Edema and Exudative AMD.
Anat Loewenstein, MD, MHA, discusses data from the Angiogenesis, Exudation, and Degeneration 2021 Virtual Symposium on angiopoietin-2/VEGF-A dual inhibition in the management of diabetic macular edema and exudative age-related macular degeneration.
2 Commerce Drive Cranbury, NJ 08512